Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Xentuzumab,Everolimus,Exemestane
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Agreement
Aragen Announces Expansion of Research Agreement with Boehringer Ingelheim
Details : Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 29, 2021
Lead Product(s) : Xentuzumab,Everolimus,Exemestane
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Exemestane
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Istituto Mario Negri | Fondazione Policlinico Universitario Agostino Gemelli | Federation of Italian Cooperative Oncology Groups
Deal Size : Inapplicable
Deal Type : Inapplicable
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
Details : Exemestane is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Exemestane
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Istituto Mario Negri | Fondazione Policlinico Universitario Agostino Gemelli | Federation of Italian Cooperative Oncology Groups
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entinostat,Exemestane,Goserelin Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial did not achieve the primary endpoint of demonstrating a statistically significant overall survival (OS) benefit over hormone therapy alone.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2020
Lead Product(s) : Entinostat,Exemestane,Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entinostat,Exemestane
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Citigroup
Deal Size : $115.0 million
Deal Type : Public Offering
Details : The Company's lead product candidate, entinostat, a class I HDAC inhibitor, is being tested in a Phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer and has been evaluated in combination with several approved PD-1...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 12, 2020
Lead Product(s) : Entinostat,Exemestane
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Citigroup
Deal Size : $115.0 million
Deal Type : Public Offering
Lead Product(s) : Entinostat,Exemestane
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
Details : Syndax Pharmaceuticals is on track to file for regulatory approval in 2020 and to become a fully-integrated oncology company with the launch of entinostat in HR+ breast cancer expected in 2021.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2020
Lead Product(s) : Entinostat,Exemestane
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable